Lyon Joseph Douglas 4
4 · CORCEPT THERAPEUTICS INC · Filed Nov 5, 2025
Insider Transaction Report
Form 4
Lyon Joseph Douglas
See Remarks
Transactions
- Exercise/Conversion
Common Stock
2025-11-03$13.56/sh+5,000$67,800→ 15,277 total - Exercise/Conversion
Stock option (right to buy)
2025-11-03−5,000→ 16,571 totalExercise: $13.56Exp: 2030-02-07→ Common Stock (5,000 underlying) - Sale
Common Stock
2025-11-03$73.65/sh−5,000$368,245→ 10,277 total
Footnotes (4)
- [F1]Includes 215 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024, 216 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025, 749 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 2, 2025 and 200 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
- [F2]The transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on August 30, 2024 in effect at the time of this transaction.
- [F3]Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $73.47 to $73.945 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
- [F4]Fully exercisable.